Insulet (NASDAQ: PODD) is one of 106 public companies in the “Surgical & medical instruments” industry, but how does it compare to its peers? We will compare Insulet to similar businesses based on the strength of its analyst recommendations, earnings, institutional ownership, profitability, risk, valuation and dividends.
Earnings and Valuation
This table compares Insulet and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Insulet||$463.77 million||-$26.83 million||-190.85|
|Insulet Competitors||$1.51 billion||$110.16 million||-199.53|
Insulet’s peers have higher revenue and earnings than Insulet. Insulet is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current recommendations and price targets for Insulet and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insulet presently has a consensus price target of $87.75, indicating a potential downside of 0.05%. As a group, “Surgical & medical instruments” companies have a potential upside of 3.25%. Given Insulet’s peers higher probable upside, analysts clearly believe Insulet has less favorable growth aspects than its peers.
This table compares Insulet and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Insulet has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Insulet’s peers have a beta of 0.77, meaning that their average share price is 23% less volatile than the S&P 500.
Institutional & Insider Ownership
49.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 3.6% of Insulet shares are owned by insiders. Comparatively, 15.8% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Insulet beats its peers on 7 of the 13 factors compared.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.